Red light therapy
and sexual health

The conversation nobody is having

Sexual health is one of the most searched health topics in the UK and one of the least openly discussed. Around 40% of adults experience some form of sexual dysfunction at some point - low libido, difficulty with arousal, performance issues, reduced sensation. The causes are usually multiple and interconnected: hormonal shifts, poor circulation, chronic stress, disrupted sleep, depression, age-related changes. Most people either live with it or try medication, and many never find a solution that works consistently.

Red light therapy does not cure sexual dysfunction. That needs to be said before anything else. But the biology connecting PBM to the underlying drivers of sexual health is more direct than most people realise - and over the past few years, the research has become specific enough to be worth discussing properly, for both men and women.

The mechanisms overlap significantly between sexes - nitric oxide, circulation, testosterone, mood, sleep - but where the evidence diverges, that is covered honestly.

The four mechanisms that connect PBM to sexual health

Sexual health depends on a cluster of physiological systems all functioning reasonably well at the same time. Healthy hormone levels, good blood flow, a nervous system not chronically in stress mode, and enough energy to sustain interest and function. PBM has documented effects on all four - and crucially, they feed into each other.

The cascade matters because it explains why the effects of consistent panel use are cumulative rather than immediate. Each mechanism reinforces the others. Someone with chronic stress, poor sleep, and low testosterone has all four pathways suppressed at once - and addressing any one of them has knock-on effects on the rest.

Erectile dysfunction affects roughly half of men over 40 to some degree, rising to around 70% of men over 70. It is primarily a vascular condition - the majority of ED cases involve insufficient blood flow into the corpora cavernosa, the erectile tissue of the penis, rather than psychological causes alone. That vascular basis is exactly why the nitric oxide mechanism of PBM is directly relevant.

The most compelling recent evidence comes from a 2025 study published in Scientific Reports (Anita/Limanjaya et al., DOI 10.1038/s41598-025-04873-w). Using LED therapy combining 660nm red and 830nm NIR light in a cavernous nerve injury mouse model - the model used to study nerve-related ED after prostate surgery - the combined wavelengths restored intra-cavernous pressure to approximately 90% of normal levels. Nerve-related ED is notoriously resistant to standard treatments including PDE5 inhibitors, which makes this a meaningful finding even accounting for the preclinical context. The mechanism identified: PBM promoted nerve regeneration and improved local vascular function simultaneously.

A 2024 study in World Journal of Men's Health (PMID 38772533) examined PBM as a potential therapy for erectile function in a cavernous nerve injury model, finding that photobiomodulation supported cavernous nerve recovery and improved erectile response. The authors concluded it warrants investigation as a non-invasive treatment option. A separate 2023 review (Kashiwagi et al., PMID 36462596) confirmed the mechanism in detail: PBM stimulates nitric oxide signalling through multiple pathways in endothelial and smooth muscle cells - the same biology that underpins normal erectile function.

The honest caveat: almost all of this evidence is preclinical. Human RCTs specifically testing red light panels for ED do not yet exist in the peer-reviewed literature. The secondary literature cites pilot studies (810nm, 630nm) with promising results in men with mild-to-moderate ED, but these are from wellness sites rather than verifiable primary sources. What is established is the mechanism and the preclinical signal - both are strong enough to justify interest, but the human trial data needs to catch up.

Female sexual dysfunction is significantly under-researched relative to male sexual dysfunction - a disparity that reflects a wider pattern in medical research. Around 40% of women experience sexual concerns at some point, including low desire, difficulty with arousal or orgasm, pain during sex, or vaginal dryness, particularly in the perimenopause and postmenopause years. The causes are even more multifactorial than in men, interweaving hormonal, psychological, relational, and physical elements.

For red light therapy specifically, the direct clinical evidence in women is limited. There is a small pilot study of intravaginal red light application for vaginal dryness (30 women, no placebo control) that reported symptom improvement - but the design is too weak to draw conclusions from, and an intravaginal device is a different tool from a home panel. The laser evidence for vaginal atrophy - which is more substantial - comes from ablative CO2 and Er:YAG devices, not red light, and cannot be attributed to a panel.

Where the case for women is stronger is through the shared mechanisms. Testosterone is the primary hormonal driver of libido in women too, albeit at much lower concentrations than in men, and its decline in perimenopause and menopause is one of the main reasons sexual desire falls. The same nitric oxide and circulation effects relevant to male sexual function also apply to female genital blood flow - arousal in women is also dependent on vasodilation and tissue engorgement. The reduction in cortisol, improvement in sleep quality, and anti-depressant effects documented for PBM are, clinically, some of the most reliable ways to improve female libido - because stress, poor sleep, and low mood are among its most common drivers.

The honest position: the systemic effects of a red light panel - better sleep, lower cortisol, hormonal support, improved energy - address several of the most common underlying causes of low female libido. Whether there is a direct local effect on female sexual tissue from external panel use is not yet established. That is a meaningful distinction and worth stating clearly.

What both sexes have in common

The strongest case for red light therapy in sexual health - for men and women equally - is not through direct genital application or any specific sexual function mechanism. It is through the systemic improvements in the underlying conditions that suppress sexual health.

Chronic stress and high cortisol are probably the most common reasons healthy people with no underlying condition experience low libido. Cortisol directly suppresses gonadotropin-releasing hormone, reducing the signal for testosterone and oestrogen production. You cannot out-supplement a stressed, sleep-deprived nervous system. PBM's documented cortisol reduction and autonomic nervous system effects - covered in the vagus nerve blog - address this pathway directly.

Sleep drives testosterone production - that much was covered in the mechanisms section. But it also drives everything else involved in sexual motivation: energy, mood, self-perception, interpersonal warmth. The flatness that comes from chronic poor sleep is one of the most reliable libido suppressants there is. PBM's effects on sleep quality are documented in the sleep blog and connect directly to this.

Depression and anxiety have a well-established bidirectional relationship with sexual function. Low libido is both a symptom and a cause of depression; anxiety impairs arousal and performance directly. PBM's anti-depressant and anxiolytic effects - including the GAD pilot showing anxiety scores halved over 8 weeks of transcranial NIR use - are clinically relevant here for both sexes.

None of this is as simple as "use a red light panel and your sex life improves." The picture is more indirect than that. But for someone whose sexual health has deteriorated alongside stress, poor sleep, low mood, and fatigue - which describes a very large proportion of the people who search for answers on this topic - addressing those root conditions through every available tool is a more rational strategy than looking for a direct sexual function fix.

Where this fits in a broader approach

Sexual health rarely deteriorates in isolation. It usually goes alongside sleep, stress, mood, and energy - and restoring it usually requires attending to all of those together rather than finding a single lever to pull.

Red light therapy is not that single lever. For men, the nitric oxide mechanism and the preclinical erectile function evidence are interesting, and the human research needs to catch up. For women, the evidence for direct sexual function effects is not yet there, but the systemic benefits address real drivers. For both, the contribution of consistent panel use to sleep quality, stress levels, hormonal environment, and mood is documented and clinically meaningful - and those factors matter for sexual health as much as anything else.

If sexual function is a specific concern, a GP or sexual health specialist should be the starting point. PBM fits as part of a broader approach to the underlying biology - not as a standalone treatment, but not as irrelevant either.